FdaApplication
NDA 212306
Identifiers
- fda_app_no: NDA212306
Properties
| Property | Value |
|---|---|
| applicant_name | KARYOPHARM THERAPEUTICS INC |
| application_type | NDA |
| approval_date | 2019-07-03 |
Revenue by product
XPOVIO
| Period | Revenue |
|---|---|
| Q2 2026 | $30.8M |
| Q1 2026 | $29.2M |
| Q3 2025 | $32.0M |
| Q1 2025 | $21.1M |
| Q3 2024 | $29.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| XPOVIO | SELINEXOR | 20MG | TABLET;ORAL |
| XPOVIO | SELINEXOR | 60MG | TABLET;ORAL |
| XPOVIO | SELINEXOR | 10MG | TABLET;ORAL |
| XPOVIO | SELINEXOR | 40MG | TABLET;ORAL |
| XPOVIO | SELINEXOR | 50MG | TABLET;ORAL |
| XPOVIO | SELINEXOR | 80MG | TABLET;ORAL |
6 products